Brief: Ampio's Phase I Study For Inhaled Ampion Advances To 2nd Group Of Covid-19 Patients
10/11/2020 21:07
Nov 10 (Reuters) - Ampio Pharmaceuticals Inc AMPE.A :
* AMPIO'S PHASE I STUDY FOR INHALED AMPION ADVANCES TO 2ND
GROUP
OF COVID-19 PATIENTS WITH RESPIRATORY DISTRESS
* AMPIO PHARMACEUTICALS - SAFETY MONITORING COMMITTEE FOUND
AMPION
TO BE SAFE AND WELL-TOLERATED AFTER REVIEWING RESULTS FROM FIRST
TREATMENT GROUP
Source text for Eikon: ID:nPnkJkyNa
Further company coverage: AMPE.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ampio Pharmaceuticals
See all newsBrief: Ampio Announces Voluntary Delisting And SEC Deregistration
Brief: Ampio Provides Update On Results From Pre-IND Enabling Studies
Brief: Ampio Selects Ascendia Pharmaceuticals, Inc. To Provide CDMO Services To Support Clinical Development Of OA-201
Brief: Ampio Pharmaceuticals Announces Reverse Stock Split
Brief: Ampio Pharmaceuticals Inc - Holds Approximately $1.25 Million In A Deposit Account At Silicon Valley Bank